Testing Effective Methods to Recruit Sexual and Gender Minority Cancer Patients for Cancer Studies

摘要：最近，NCI呼吁进行研究，以有效地研究与癌症相关的少数或稀有人群 研究。性少数群体和性别少数群体(SGM)是罹患癌症和 在癌症研究中研究不足。本行政补充申请，回应MD-22- 032，寻求资金以解决性少数群体和性别少数研究中一个重要的、不可预见的挑战 癌症患者。在整个SGM中，共同主要挑战是开发有效的方法来确定和 招募这样的患者和幸存者参加NCI癌症研究。在母公司研究的目标1中，我们将记录 深度，SGM对参与NIH癌症研究的态度，确定 影响参与意愿。我们还将调查任何影响歧视和癌症护理不善的问题 对研究参与度的影响。我们将招聘顺性短信男性、顺性短信女性和性别少数民族 癌症患者(每组15人)，并比较这些小人群中和SGM之间的经历 以及一组顺性、异性恋患者作为对照组。 这种方法将促进我们对为什么SGM可能被遗漏或系统地排除的理解 来自癌症研究。最近，研究人员强调了将性别少数群体崩溃为 一个单一的类别。性别非二进制是一个快速增长的身份标签，代表认同 与女性或男性不同(或不完全是)的性别，个人可能会也可能不会认为 变性人(TG)。因此，非二进制患者在癌症治疗方面可能面临与TG不同的挑战 患者，值得单独研究。同样，TG男性和TG女性可能会有不同的 治疗体会。将这些性别群体聚集在一起可能会掩盖重要的亚群 不同之处。出于这个原因，我们寻求扩大我们目前的研究。与其将性别少数群体崩溃为 作为一个单独的小组，我们将招募和面试多达15名TG男性、15名TG女性和15名非二元患者(N=45 Total)对他们的癌症治疗经验和对参与NIH癌症的态度进行了调查 研究。这一形成研究阶段的结果将告诉我们如何对待性别少数群体数据 AIM 3.Impact中的定量研究包括有史以来第一次对性别非二元癌症患者进行的研究。

Abstract: Recently, NCI called for research to effectively study small or rare populations relevant to cancer research. Sexual and gender minorities (SGM) are small populations at disproportionate risk for cancer and are under-researched in cancer studies. This administrative supplement application, in response to MD-22- 032, seeks funding to address an important, unforeseen challenge in research on sexual and gender minority cancer patients. The principal challenge common across SGM is to develop effective methods to identify and recruit such patients and survivors into NCI cancer studies. In Aim 1 of our parent study, we will document, in depth, SGM’s attitudes towards participating in NIH cancer research, identifying facilitators and barriers that influence willingness to participate. We will also investigate any impact discrimination and poor cancer care has on research participation. We will recruit cisgender SM men, cisgender SM women and gender minority cancer patients (n=15 per group) and compare experiences within these small populations and between SGM and a cisgender, heterosexual patient comparison group. This approach will advance our understanding of why SGM may be missing or systematically excluded from cancer studies. Recently, researchers have highlighted the limitations of collapsing gender minorities into a single category. Gender nonbinary is a fast-growing identity label that represents persons who identify with a gender different than (or not exclusively as) woman or man and who may or may not personally identify as transgender (TG). As such, nonbinary patients may have different challenges in cancer treatment than TG patients and deserve to be studied separately. Similarly, TG men and TG women are likely to have different experiences of treatment. Aggregating these gender groups into one may mask important subgroup differences. For this reason, we seek to expand our current study. Instead of collapsing gender minorities into a single group, we will recruit and interview up to 15 TG men, 15 TG women, and 15 nonbinary patients (N=45 total) on both their experience of cancer treatment and on their attitudes towards participating in NIH cancer research. Results from this formative research phase will inform how to treat gender minority data for our quantitative study in Aim 3. Impact includes the first study of gender nonbinary cancer patients ever conducted.